Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases
Association between Homocysteine Levels and All-cause Mortality: A Dose-Response Meta-Analysis of Prospective Studies
Histidine is decreased in inflammatory diseases such as Takayasu arteritis, systemic lupus erythematosus, and rheumatoid arthritis 29,30,31
New to retinol
Specifications, Standards & Compliance Ensure products comply with ISO 13485:2016 (medical device quality management) and REACH/CE certifications for EU markets
NOX enzymes and new thinking on reactive oxygen: A double-edged sword revisited
